Dirk Arnold
Impact in
- Oncology top 0.05%
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Surgical Treatments
- Pancreatic and Hepatic Oncology Research
- Hepatology top 0.5%
- Hepatocellular Carcinoma Treatment and Prognosis
Papers in
- Oncology 177
- Colorectal Cancer Treatments and Studies 137
- Cancer Treatment and Pharmacology 39
- Colorectal Cancer Surgical Treatments 30
-
- Gastric Cancer Management and Outcomes 54
- Lung Cancer Treatments and Mutations 24
- Co-authors
- Andrés Cervantes (22 shared papers)Emmanuel Tiret (2 shared papers)Bernard Nordlinger (3 shared papers)Bengt Glimelius (1 shared paper)Eric Van Cutsem (25 shared papers)Rob Glynne‐Jones (6 shared papers)Karin Haustermans (5 shared papers)David Cunningham (14 shared papers)
- Journals
- Journal of Clinical Oncology (65 papers)Annals of Oncology (48 papers)BMC Cancer (10 papers)ESMO Open (6 papers)Clinical Colorectal Cancer (5 papers)
- Partner nations
- GermanyFranceUnited States
In The Last Decade
Dirk Arnold
255 papers receiving 17.2k citations
Dirk Arnold's Hit Papers
Peers
Comparison fields: 5 of 142
- Oncology 9.0k
- Hepatology 1.4k
- Pulmonary and Respiratory Medicine 3.9k
- Surgery 4.5k
- Cancer Research 1.4k
Countries citing papers authored by Dirk Arnold
This map shows the geographic impact of Dirk Arnold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk Arnold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk Arnold more than expected).
Fields of papers citing papers by Dirk Arnold
This network shows the impact of papers produced by Dirk Arnold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk Arnold. The network helps show where Dirk Arnold may publish in the future.
Co-authors
The 25 scholars most cited alongside Dirk Arnold, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 274 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2013 | 1431 |
| 2 | Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2017 | 1340 |
| 3 | Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2013 | 1097 |
| 4 | Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2016 | 1096 |
| 5 | Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2015 | 952 |
| 6 | Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2014 | 891 |
| 7 | Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Hit paper breakdown → | 2022 | 859 |
| 8 | Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial Hit paper breakdown → | 2012 | 843 |
| 9 | Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2016 | 772 |
| 10 | Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials Hit paper breakdown → | 2017 | 562 |
| 11 | Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2016 | 481 |
| 12 | Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2014 | 389 |
| 13 | Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines Hit paper breakdown → | 2021 | 313 |
| 14 | 2014 | 289 | |
| 15 | 2013 | 240 | |
| 16 | 2016 | 217 | |
| 17 | 2019 | 207 | |
| 18 | 2008 | 196 | |
| 19 | 2014 | 185 | |
| 20 | 2013 | 182 |
About Dirk Arnold
Dirk Arnold is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Pathology and Forensic Medicine and Hepatology, having authored 274 papers that have together received 17.4k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (137 papers), Gastric Cancer Management and Outcomes (54 papers), Cancer Treatment and Pharmacology (39 papers), Colorectal and Anal Carcinomas (32 papers), Colorectal Cancer Surgical Treatments (30 papers), Lung Cancer Treatments and Mutations (24 papers), Genetic factors in colorectal cancer (23 papers) and Hepatocellular Carcinoma Treatment and Prognosis (22 papers). The work is most often cited by research in Oncology (9.0k citations), Hepatology (1.4k citations), Pulmonary and Respiratory Medicine (3.9k citations), Surgery (4.5k citations) and Cancer Research (1.4k citations). Dirk Arnold has collaborated with scholars based in Germany, France and United States. Frequent co-authors include Andrés Cervantes, Emmanuel Tiret, Bernard Nordlinger, Bengt Glimelius, Eric Van Cutsem, Rob Glynne‐Jones, Karin Haustermans, David Cunningham, Marcel Verheij and William Allum. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, BMC Cancer, ESMO Open and Clinical Colorectal Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.